trending Market Intelligence /marketintelligence/en/news-insights/trending/Tf5qH9AAA4ENvXCEqa5HIQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

InMed Pharmaceuticals plans private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

InMed Pharmaceuticals plans private placement

InMed Pharmaceuticals Inc. said it will offer up to 3,572,000 units via a nonbrokered private placement with certain investors.

The units will be priced 70 Canadian cents apiece, for gross proceeds of up to C$2.5 million.

Each unit will include 1 common share and 1 nontransferable share purchase warrant. Each warrant can be used to buy 1 additional common share at C$1.25 for a period of 18 months from the closing of the offering.

InMed plans to use net proceeds to advance the company's drug development programs and for general working capital and corporate purposes.

Dates for separate closings for individual subscriptions will be determined by the company.

Closings are expected to occur on or before Dec. 22.